*Sponsored by ENvue Medical, Inc
A leading nonprofit health system running 12 hospitals across Virginia and North Carolina recently made the platform its standardized protocol for bedside feeding tube placement, extending the relationship through 2028
The ENvue System is FDA 510(k) cleared and currently in use at hospitals across the United States
According to Yahoo, FEED on has just over 6M Shares
_________________________
Hello Everyone,
We have something for you to keep an eye on for today’s session. Research this one right away.
The real story is in the float. According to Yahoo, FEED on has just over 6M Shares.
5 Catalysts to pay attention to for ENvue Medical, Inc. (Nasdaq: FEED) for today:
1. Three Distinct Platforms in One Company: ENvue Medical isn’t a one-product story—it runs three separate device platforms targeting feeding tube placement, chronic pain, and hospital-acquired infections.
2. GPS-Style Feeding Tube Navigation: The ENvue System uses electromagnetic field technology and built-in sensors to create a real-time body map, showing providers exactly where a feeding tube is traveling—like GPS for the inside of the body.
3. A Genuine Patient-Safety Problem: Misplaced feeding tubes can enter the airway instead of the digestive tract, with consequences that can be severe or even fatal. The system’s red-arrow alerts warn when the tube approaches the airway.
4. FDA-Cleared and Already in Hospitals: The ENvue System is FDA 510(k) cleared and currently in use at hospitals across the United States.
5. Becoming Standard of Care: A leading nonprofit health system running 12 hospitals across Virginia and North Carolina recently made the platform its standardized protocol for bedside feeding tube placement, extending the relationship through 2028.
Across the United States, hospitals perform more than 13M feeding tube placements every year — yet a staggering 85% of those procedures are still performed blindly, without any real-time visual guidance, forcing clinicians to wait on radiology confirmation before a single drop of nutrition can reach a patient.
(FEED) built its platform specifically to fix that problem — and this week, independent peer-reviewed science confirmed that it works.
A study just published in the official journal of the American Association of Critical Care Nurses showed the ENvue™ Navigation Platform saved over 350 nursing hours in year one, cut repeat imaging by 20%, and reduced hospital-acquired aspiration pneumonia by 20% across a multi-hospital health system.
Those aren’t projections. They are real-world, independently documented clinical outcomes.
The commercial story around this name has been developing fast — and there are now even more reasons to have FEED on your radar this morning.
The company operates two distinct technology platforms that together address a wide range of clinical and home-care needs.
The ENvue™ Navigation Platform is a minimally invasive electromagnetic navigation system that assists clinicians in placing nasoenteral feeding tubes at the bedside with real-time visual guidance.
The system is FDA 510(k) cleared for adult use and is now commercially deployed across 40 U.S. hospitals, generating recurring consumable revenue as clinicians integrate it into their daily workflow.
The company’s second platform, the Acoustic Therapeutic Platform, includes PainShield® and UroShield® — devices utilizing proprietary low-intensity surface acoustic wave (SAW) technology designed for pain reduction, biofilm disruption, and bacterial colonization prevention in home and clinical settings.
UroShield recently secured reimbursement approval in the UK, adding an international revenue channel through distributor Peak Medical.
Leadership is anchored by Doron Besser, MD, Chief Executive Officer, with Marc Waldman serving as VP of Commercial — bringing over 35 years of medical device commercial leadership to the role. David Johnson serves as Chairman of the Board.
ENvue Medical (NASDAQ: FEED) Just Unlocked the Recurring Revenue Story Investors Have Been Waiting For
ENvue Medical has just introduced Ask Oscar™, an AI-powered training platform that goes straight at the single biggest bottleneck standing between any medical technology and full-scale hospital adoption: training. And the way management is framing it, this isn’t a side feature — it’s the layer that changes the entire economics of how ENvue scales.
Here’s the problem Ask Oscar was built to solve. Hospitals are stretched thin, clinicians rotate shifts constantly, and every new competency requirement means pulling a specialist on-site to train nurses and dietitians in person. That bottleneck has quietly capped how fast even great medical technology can spread through a health system. Ask Oscar removes it entirely by letting clinicians train independently, on their own schedule, with the platform monitoring procedural performance in real time, catching deviations, and delivering immediate corrective coaching — no educator required to be standing in the room.
That alone would be a meaningful operational upgrade. But the real signal for investors is what CEO Doron Besser is saying about the business model underneath it: Ask Oscar is expected to be commercially available within the coming months across ENvue’s entire installed hospital base, and management is positioning it as a scalable, recurring revenue stream layered directly on top of the existing Navigation Platform footprint. In other words, ENvue isn’t just selling more hardware into hospitals — it’s building a second revenue engine on top of the customers it’s already won.
And Ask Oscar isn’t a standalone side project. It’s built on ENvue’s existing navigation and training infrastructure, and every session run through the platform generates data that feeds an intelligence layer designed to support the Company’s broader roadmap — including ENvue Drive, its patent-pending robotic-assisted feeding tube placement initiative. Management describes the foundation here as extending well beyond training itself, toward future intelligent guidance and advanced procedural assistance across the entire ENvue ecosystem.
This launch also doesn’t happen in a vacuum — it lands right behind a landmark independent, peer-reviewed study published in Critical Care Nurse that put hard numbers behind the ENvue Navigation Platform’s clinical impact: zero lung placements across 531 consecutive procedures, a 67% reduction in ventilator-associated pneumonia, a staggering 4,320% increase in post-pyloric feeding access, more than 350 nursing hours freed annually, and over $1.5 million in annual cost avoidance within a single health system. That’s the kind of validation that turns a sales conversation into a standard-of-care decision — and now ENvue is pairing that clinical credibility with an AI layer designed to make adoption faster and stickier across every account it touches.
Put simply: ENvue just gave hospitals a faster way to say yes, and gave itself a new way to get paid for it.
Burn ICU Expansion Signals Growing Clinical Versatility
Two days after that publication, on June 5, 2026, FEED announced that a major U.S. academic health network has expanded its use of the ENvue™ Navigation Platform into its American Burn Association-verified burn intensive care unit — marking the second deployment within the same health system.
Burn ICU patients represent one of the most clinically challenging and vulnerable populations in hospital medicine. Feeding tube placement in this setting carries elevated risk, and the decision to expand an existing platform relationship into the burn ICU — rather than simply maintaining current deployments — signals a level of institutional trust that goes well beyond standard contract renewals.
CEO Doron Besser, MD, addressed it directly: “We believe that this health network’s decision to bring the ENvue Navigation Platform into their burn ICU speaks directly to the clinical versatility of our platform and institutional trust that we have earned with this network.”
The fact that this expansion occurred within a health system already using the platform — and came just days after peer-reviewed clinical results from a multi-hospital Inova deployment — suggests a pattern of deepening institutional commitment rather than one-off adoption.
Commercial Momentum: The Bigger Picture
Before these two most recent developments, FEED had already been building a compelling commercial foundation:
On May 12, 2026, FEED announced that its ENvue™ Navigation Platform was adopted as the standardized protocol for bedside feeding tube placement across a 12-hospital integrated non-pro-fit health network in Virginia and North Carolina — a three-year renewal running through 2028. Standardized protocol status means the platform is embedded directly into clinical workflow as the method of care, driving consistent utilization across the network rather than simply being available for optional use.
On May 7, 2026, FEED locked in a three-year GPO purchasing agreement renewal tied to one of the largest non-pro-fit health systems in the U.S. — encompassing more than 90 hospitals across 17 states.
Any participating hospital can now move directly to adoption without navigating lengthy value analysis committee approvals. CEO Doron Besser, MD, stated the arrangement makes the platform “one clinical decision away from adoption” at any participating facility.
FEED also holds two recently issued USPTO Notices of Allowance — one covering a next-generation feeding tube combining electromagnetic navigation with a distal-tip camera, and a second covering SAW technology applied to transdermal compound delivery — broadening the IP portfolio into pain management, neurology, and inflammation applications.
NEWS
June 9, 2026
ENvue Medical Launches AI Training Platform Establishing Artificial Intelligence Foundation for Robotic Feeding Tube Navigation
June 5, 2026
ENvue Medical Expands into Burn Intensive Care Unit at Major Academic Health Network
June 3, 2026
ENvue Medical Announces Publication of Landmark Independent Study Highlighting Significant Safety, Time-, and Cost-Saving Benefits of ENvue Navigation Platform in Multi-Hospital System
May 19, 2026
ENvue Medical to Showcase ENvue™ Navigation Platform at AACN NTI 2026
May 12, 2026
ENvue Medical Secures Three-Year Contract Renewal at 12-Hospital U.S. Health Network as the ENvue™ Navigation Platform Becomes Standard of Care
May 8, 2026
ENvue Medical Adds to Intellectual Property Portfolio by Securing USPTO Notice of Allowance for Ultrasound-Enhanced Cannabinoid Drug Delivery Technology
May 7, 2026
ENvue Medical Secures Three-Year Purchasing Agreement Renewal with the Group Purchasing Organization (GPO) for One of the Largest Health Systems in the U.S. Operating Over 90 Hospitals
April 16, 2026
ENvue Issues Stockholder Letter & Provides Corporate Update
March 24, 2026
ENvue Medical Expands Presence within a Major Michigan Health System and Grows U.S. Hospital Footprint to 39
MANAGEMENT
Doron Besser, M.D.
Chief Executive Officer
Doron Besser is the CEO of ENvue Medical and NanoVibronix (Nasdaq: NAOV), overseeing the integration of the two divisions: electromagnetic navigation for enteral feeding (ENvue) and non-invasive therapeutic devices for pain and urology (NanoVibronix).
Doron is continuing the advancement and commercialization of ENvue navigation system for enteral feeding, leading global strategy, clinical education, commercialization in the U.S. and ROW, and expansion into new applications including pediatrics and vascular access.
Prior to managing both divisions, Doron co-founded and managed ENvizion Medical and Swing Medical, a private equity investment fund. Doron guided ENvizion Medical from concept to FDA clearance, built U.S. clinical adoption, and launched the ENvue system into hospitals as a next-generation navigation platform.
Doron also co-founded and led NutriSeal, a company focused on preventing nasoenteral-induced gastric reflux and ventilator-associated pneumonia (VAP). Prior to NutriSeal, Doron served as CEO of Angioslide Ltd., a company specializing in innovative, cost effective angioplasty products. Doron guided the company through its infancy stages, which included complicated animal and human trials, to FDA clearance, CE approval and initial market penetration in Europe and the US. Doron also served as VP of Clinical and Marketing and VP of Business Development at super Dimension, a leader in minimally-invasive pulmonology devices. Doron helped lead super Dimension from its inception, serving on the core team that identified opportunities within the pulmonology market. In 2012, Covidien acquired superDimension for ~$300 million.
As a seasoned entrepreneur, Doron specializes in identifying breakthrough technologies and developing them throughout all product development phases, including international sales and marketing activities.
He holds a Doctor of Medicine degree from Munich’s Ludwig-Maximilians University.
Zenya Gorlik
VP R&D
Zenya Gorlik is a seasoned software expert with over 20 years of experience in developing large-scale multidisciplinary projects in military and medical industries from geographic information systems for intelligence to MRI medical devices and beyond. He specializes in managing projects end-to-end from concept to delivery.
Before joining ENvue Medical in 2021, Zenya served as senior software engineer and team leader at Camtek, ImageSat International, and Aspect Imaging, as software consultant at CodeValue, and more.
He holds a BA in mathematics and computer science from Haifa University, and is certified as a systems analysis engineer by the Technion Institute of Technology.
Anat Hofshi, PhD
VP Clinical Affairs & Product
With a great belief in technologies that can improve patient safety, Dr. Hofshi joined ENvue Medical in 2016 to lead the clinical activities and trials required to finalize the R&D phase and to commercialize the ENvue system in the US. Dr. Hofshi brings outstanding ability to interconnect between different disciplines areas and a high level of practical and hands-on skills.
Previous to her joining ENvue, Dr. Hofshi, served as a Project Leader at B.G. Guard and Carmel StemSense, startup companies in the field of Diabetics.
Dr. Hofshi holds a B.S.c in Biotechnology and Food engineering and a PhD from the Department of Physiology and Biophysics, Technion Institute, specializing in Electrophysiology, Stem Cells and Cardiovascular Regenerative Medicine. Dr. Hofshi received many awards and honors for her scientific accomplishments (Wolf, etc.).
SINCERELY,
DISCLAIMER
MicroCapAlerts.io is owned by Dedicated Investors, LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.
The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell. The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.
Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.
The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.
The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.
The Information published by the Publisher may recommend that investors buy the Issuers’ shares while the Paying Party and/or their affiliates sell their shares of the Issuers. When the Paying Party sells their shares, the Issuers’ stock price may decline and thereby dramatically reduce the price at which investors can sell their shares. As such, investors who purchase the Issuers’ shares during the Publication of the Information will likely pay inflated prices. The Paying Party may sell the Issuers’ securities for less than the target prices set forth in the Information. The Paying Party and its affiliates may make substantial profits by selling their securities during the Publication of the Information while investors experience losses.
The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability, and disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the information is at your own risk. The Information is provided “as is” without any warranties of any kind without limitation. The Publisher does not verify or confirm any portion of the Information and does not conduct any due diligence or research on any aspect of the Information, including the completeness, accuracy, truthfulness or reliability of the Information.
Investors should not rely upon the Information for any purpose and should contact a licensed investment advisor and their legal advisor and review all documents about the Issuers with the assistance of such advisors, including documents publicly filed on www.sec.gov and http://www.OTCMarkets.com to obtain information about the Issuers.
Before investing in any public company, you should conduct your own in-depth investigation with the assistance of your legal, tax and investment advisors of the Issuers’ financial condition, operations, management, products or services, trends in the industry, the Issuers’ trading history, short sale positions and risks that may be material to its business and other information you and your advisors deem material to an investment decision. This investigation should include, but not be limited to, a review of available public sources and information you receive directly from http://www.OTCMarkets.com and www.sec.gov.
The Publisher is not and does not act in the capacity of any of the following and is not qualified to do so; as such, you should not construe the Publisher’s activities as involving any of the following:
▪ An independent advisor or consultant;
▪ Providing investment advice or acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
▪ Broker-dealer activities or acting in the capacity of a registered representative or broker;
▪ Stock picker;
▪ Securities trading expert;
▪ Securities researcher or analyst;
▪ Financial planner or financial planning;
▪ Provider of stock recommendations;
▪ Provider of advice about buying and selling or holding recommendations as to specific securities; or
▪ Making an offer or sale of securities or solicitation to purchase securities.
An investment in the Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Publication of the Information. Favorable past performance of the Issuers does not guarantee future results. If you purchase the securities of the Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Issuers include but are not limited to the risks stated below.
▪ The Information is not a solicitation or recommendation to buy, sell or hold securities, and the Publisher does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Information or the Issuers and does not receive any verification from any party regarding the Information.
▪ If the Publisher publishes any percentage gain of the Issuers’ share from the previous day’s close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
▪ The Information may contain statements that Issuers’ stock price has increased over a certain period of time, which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon such information in your analysis of the present or future potential of the Issuers or its securities.
▪ The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Issuers’ future stock price or future financial performance.
▪ You may encounter difficulties determining what, if any, portions of the Information are material or nonmaterial, making it all the more imperative that you conduct your own independent investigation of the Issuers and its securities with the assistance of your legal, tax and financial advisor.
▪ If the Information states that its securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that Publisher states may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.
▪ The Information contains forward-looking statements, i.e., statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Issuers with the assistance of your lawyer, tax advisor and investment advisor as well as any such forward-looking statements. Any forward-looking statements made in the Information are limited to the time period in which they are made, and the Publisher does not undertake to update forward-looking statements that may change at any time.
▪ The Information is presented only as a brief snapshot of the Issuers and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Issuers and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov or other electronic medium, including: (a) reviewing Information and Disclosure Statements and unaudited financial reports filed with the www.otcmarkets.com; (b) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (c) investment guides at www.sec.gov and www.finra.org. You should always be concerned that the Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com. You should only invest with the assistance of your attorney, lawyer and tax advisor after they have conducted exhaustive due diligence on the particular Issuer and its trading activity.
▪ The Publisher may hire third-party service providers and stock promoters to electronically disseminate live news about the Issuers, yet the Publisher has no control over the content of and does not verify the information that these service providers publish.
The Publisher or its officers, directors, owners, managers, affiliates and control persons were paid to publish the Information about the issuers identified below:
Name of Issuer: ENvue Medical, Inc
Amount of Cash Compensation: fifteen thousand usd
Period of Publication of Information: One day campaign beginning and ending on July ninth twenty twenty six
Where Information is Published: MicroCapAlerts.io Website, Email Campaign, SMS Campaign, Social Media including but not limited to: Youtube, X, Tiktok, Instagram, Stock Twits, Reddit, Discord.
By reading the Information and visiting the Platform, you agree you have not relied on the Information and agree to indemnify, defend and hold the Publisher harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information without limitation.